Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyrantel is an oral anthelmintic (anti-worm) medication used to treat a variety of intestinal worm infections including pinworm (Enterobiasis), roundworm (Ascariasis), and hookworm. It acts as a depolarizing neuromuscular-blocking agent in susceptible nematodes by promoting the release of acetylcholine and inhibiting cholinesterase. This causes persistent activation of nicotinic receptors on the parasite's muscle cells leading to spastic paralysis; the paralyzed worms are then expelled from the body via normal peristalsis. Pyrantel is poorly absorbed from the gastrointestinal tract in humans and is typically administered as a single dose for pinworms or roundworms and over several days for hookworms[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrantel.